A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Status:
Recruiting
Trial end date:
2023-12-19
Target enrollment:
Participant gender:
Summary
The reason for this study is to see how safe and effective the study drug donanemab is in
participants with early Alzheimer's disease.
Additional participants will be enrolled to an addendum safety cohort. The participants will
be administered open-label donanemab.